ExitHealthcare
Brandon Capital sells Myricx Bio to Novartis
The deal, valued at up to $1.5 billion, gives Novartis a novel NMTi-ADC payload platform and lead assets for multiple solid tumor indications.
- Target
- Myricx Bio
- Seller
- Brandon Capital
- Source
- GlobeNewswire